科兴制药: 股东询价转让结果报告书暨持股5%以上股东权益变动触及1%整数倍的提示性公告

Core Viewpoint - The announcement details the results of a share transfer by Shenzhen Keyi Pharmaceutical Holdings Co., Ltd., which is the controlling shareholder of Kexing Pharmaceutical Co., Ltd. The transfer involves 6,037,717 shares at a price of 36.70 yuan per share, leading to a dilution of the controlling shareholder's stake from 63.89% to 60.38% [1][3]. Group 1: Transfer Details - The share transfer price is set at 36.70 yuan per share, with a total of 6,037,717 shares being transferred [1]. - The controlling shareholder, Keyi Pharmaceutical, is involved in this transfer, which is classified as a passive dilution and will not change the actual controller of the company [1][5]. - After the transfer, Keyi Pharmaceutical and its concerted actor, Deng Xueqin, will hold a total of 121,515,555 shares, reducing their ownership percentage from 63.89% to 60.38% [2][3]. Group 2: Shareholder Information - Keyi Pharmaceutical is the controlling shareholder and is controlled by Deng Xueqin, who is also the chairman of the company [2]. - The total share capital of the company increased from 199,642,250 shares to 201,257,250 shares due to this transfer [2]. - The ownership percentage of Keyi Pharmaceutical and its concerted actor will decrease from 63.89% to 60.38% following the transfer [3]. Group 3: Regulatory Compliance - The share transfer process was reviewed by China International Capital Corporation, which confirmed that it adhered to fair and just principles and complied with relevant securities market regulations [5]. - The transfer process followed the guidelines set forth by various laws and regulations, ensuring compliance with the requirements for share transfers in the market [5].